15 research outputs found
Book Reviews
Congress and the Court By Walter F. Murphy. Chicago: The University of Chicago Press, 1962. Pp. xi, 308. 4.00. (tax law)
reviewer: Stanley D. Rose
=================================
Expulsion or Oppression of Business Associates By F. Hodge O\u27Neal and Jordan Derwin. Durham, N.C.: Duke University Press,1961. Pp. vii, 263. 5.00. (tax law)
reviewer: Harold G. Wren
===============================
Corporate Liquidations for the Lawyer and the Accountant By Howard A. Rumpf. Englewood Cliffs, N.J.: Prentice Hall, Inc.:1962. Pp. 238. 12.00. (jurisprudence)
reviewer: Robert N. Covingto
A Comparison of the Kuhlmann-Anderson Intelligence Test with the Revised Stanford-Binet, Form L
Design and fabrication of an erectable truss for precision segmentedreflector application
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m2 i.v. over 1 h on days 1 to 10. Fifty-three subjects enrolled with a median age of 74 years (range, 60–85). Nineteen (36%) had antecedent hematologic disorder or therapy-related AML; 16 had complex karyotypes (≥3 abnormalities). The complete remission rate was 47% (n = 25), achieved after a median of three cycles of therapy. Nine additional subjects had no morphologic evidence of disease with incomplete count recovery, for an overall response rate of 64% (n = 34). Complete remission was achieved in 52% of subjects presenting with normal karyotype and in 50% of those with complex karyotypes. Median overall and disease-free survival durations were 55 and 46 weeks, respectively. Death within 30 days of initiation of treatment occurred in one subject (2%), death within 8 weeks in 15% of subjects. Given the DNA hypomethylating effect of decitabine, we examined the relationship of clinical response and pretreatment level of miR-29b, previously shown to target DNA methyltransferases. Higher levels of miR-29b were associated with clinical response (P = 0.02). In conclusion, this schedule of decitabine was highly active and well tolerated in this poor-risk cohort of older AML patients. Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment